(Reuters) -Johnson & Johnson said on Thursday it has enrolled about 45,000 participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate and that it expects interim data by late-January.
The company, however, is lagging rivals Pfizer Inc and Moderna Inc in the race for a vaccine to combat the COVID-19 pandemic that has infected about 75 million people globally.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!